Daiichi Sankyo Co. said on Tuesday it fell into the red for the fiscal third quarter and further lowered its full-year outlook, hurt again by the stubbornly strong yen and legal costs associated with its Indian unit. The Japanese firm acquired a little more than 60% of Indian generic drugmaker Ranbaxy Laboratories Ltd. for $4.6 billion in 2008. But U.S. government allegations of improper manufacturing practices and data falsification have prevented the company from fully benefiting from the pricey deal. For the October-December quarter, Japan’s third-biggest pharmaceutical company by market capitalization logged a net loss of ¥19.5 billion ($255.4 million), compared with a profit of ¥27.5 billion a year earlier.
